Multiple dose study of interactions between artesunate and artemisinin in healthy volunteers
Open Access
- 1 October 2001
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 52 (4) , 377-385
- https://doi.org/10.1046/j.0306-5251.2001.01461.x
Abstract
To investigate whether coadministration of the antimalarials artesunate and artemisinin alters the clearance of either drug. Ten healthy Vietnamese males (Group AS) were randomized to receive a single dose of 100 mg oral artesunate (pro-drug of dihydroartemisinin) on day -5 and then once daily for 5 consecutive days (days 1-5). Oral artemisinin (500 mg) was coadministered on days 1 and 5. Another 10 subjects (Group AM) were given 500 mg oral artemisinin on day -5 and then further doses on days 1-5. Artesunate 100 mg was given on days 1 and 5. Artemisinin and dihydroartemisinin plasma concentrations on days -5, 1 and 5 were quantified by h.p.l.c. with on-line postcolumn derivatization and u.v. detection. In Group AS, dihydroartemisinin oral clearance values (mean (95% CI)) were similar on day 1 (32 (22, 47)) l h(-1) and day 5 (38 (28, 51)) l h(-1) of daily artesunate administration but these mean values were approximately three fold higher compared with day -5 after a single dose (95 (56, 159)). In this group, artemisinin oral clearance increased from 196 (165, 232) l h(-1) on day 1-315 (241, 410) l h(-1) on day 5. In Group AM, dihydroartemisinin oral clearance on day 1 was 39 (34, 46) l h(-1) and increased 1.6 fold to 64 (48, 85) l h(-1) on day 5. In this group, artemisinin oral clearance increased sequentially (1.5 and 4.7 fold, respectively) from 207 (151, 285) l h(-1) on day -5-308 (257, 368) l h(-1) on day 1 and to 981 (678, 1420) l h(-1) on day 5. The increase in artemisinin oral clearance between days -5 and 1 (in the absence of artesunate) was similar to that between days 1 and 5 in Group AS subjects who took daily artesunate. Dihydroartemisinin was not a significant metabolite of artemisinin. Artesunate (dihydroartemisinin) did not alter the elimination of artemisinin. However, dihydroartemisinin elimination was inhibited by artemisinin. Artemisinin induced its own elimination even 5 days after a single oral dose. There was no evidence for the formation of dihydroartemisinin from artemisinin.Keywords
This publication has 27 references indexed in Scilit:
- Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisininBritish Journal of Clinical Pharmacology, 1999
- Population pharmacokinetics and therapeutic response of CGP 56697 (artemether+benflumetol) in malaria patientsBritish Journal of Clinical Pharmacology, 1998
- Assessment of the effect of malaria infection on hepatic clearance of dihydroartemisinin using rat liver perfusions and microsomesBritish Journal of Pharmacology, 1998
- Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malariaBritish Journal of Clinical Pharmacology, 1998
- A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malariaBritish Journal of Clinical Pharmacology, 1998
- Comparison of artemisinin suppositories, intramuscular artesunate and intravenous quinine for the treatment of severe childhood malariaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1997
- A Trial of Artemether or Quinine in Children with Cerebral MalariaNew England Journal of Medicine, 1996
- Treatment Of Multidrug-Resistant Plasmodium Falciparum Malaria With 3-Day Artesunate-Mefloquine CombinationThe Journal of Infectious Diseases, 1994
- QinghaosuThe Lancet, 1993
- The prevention of antimalarial drug resistancePharmacology & Therapeutics, 1990